Lxrx stock earnings

Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Stock ...

LXRX Stock Price Quote & News - Lexicon Pharmaceuticals ... View the real-time LXRX price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Lexicon Pharmaceuticals against related stocks people have also bought like ACB, NIO, HEXO, and VKTX. 6,778 people own Lexicon Pharmaceuticals on … LXRX - Stock quote for LEXICON PHARMACEUTICALS, INC. - MSN ... View the latest LXRX stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of LEXICON PHARMACEUTICALS, INC.. Earnings Call Transcript

12 Mar 2020 LXRX earnings call for the period ending December 31, 2019. For the full-year 2019, net income included non-cash, stock-based 

Lexicon Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. LXRX updated stock price target summary. LXRX -- Is Its Stock Price A Worthy Investment? Learn More. LXRX Stock Summary. With a price/earnings ratio of 2.74, Lexicon Pharmaceuticals Inc P/E ratio is greater than that of about only 1.96% of stocks in our set with positive earnings. Equity multiplier, or assets relative to shareholders' equity, comes in at 44 for Lexicon Pharmaceuticals Inc; that's greater than it is for 99.49% of US stocks. LXRX - Lexicon Pharmaceutcl Stock Price - Barchart.com

Lexicon Pharmaceuticals Inc. (LXRX) Earnings

Lexicon Pharmaceuticals, Inc. (LXRX) Analyst Ratings ... See Lexicon Pharmaceuticals, Inc. (LXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Lexicon Pharmaceuticals, Inc. - LXRX - Stock Price Today ... View Lexicon Pharmaceuticals, Inc. LXRX investment & stock information. Get the latest Lexicon Pharmaceuticals, Inc. LXRX detailed stock quotes, stock … Stock Earnings - TD Ameritrade Oct 23, 2019 · TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. LXRX's fiscal year ends in December. Market Lexicon Pharmaceuticals, Inc. Revenue & Earnings Per Share ...

LXRX Lexicon Pharmaceuticals, Inc. — Stock Price and ...

LXRX. ATTRACTIVE: Lexicon Pharmaceuticals's price/earnings ratio of 1.6 is less than the industry average for biotechnology stocks listed on the NASDAQ.

All earnings call transcripts on Lexicon Pharmaceuticals, Inc. (LXRX) stock. Read or listen to the conference call. Download the investor presentation - earnings call slides.

LXRX Stock Price | Lexicon Pharmaceuticals Inc. Stock ... Lexicon stock tanks after Sanofi ends partnership. Shares of pharmaceutical company Lexicon Pharmaceuticals, Inc. (LXRX) are falling in Friday's after-hours market, after the company said it received notice that Sanofi wanted to terminate an alliance around the … Lexicon Pharmaceuticals, Inc. - TheStreet - Stock Market Lexicon Pharmaceuticals To Host Fourth Quarter And Full-Year 2019 Financial Results Conference Call And Webcast On March 12, 2020 By GlobeNewswire Mar 5, 2020 7:00 AM EST

Stock LXRX Price as of: MAR 06, 11:42 AM EDT $2.35 -0.11 -4.47% Expected earnings growth outside the normal range compared to benchmark/average industry growth rate/competitors. DARS Rating Get Email Updates Join over 100,000 investors who get the latest news from Dividend.com. 2 Stocks Soar on Earnings Beats - Schaeffers Research Sep 11, 2019 · LXRX stock hit a seven-week high of $2.71 earlier, and is now testing its footing atop its 40-day moving average -- a trendline it hasn't even touched since its late-July bear gap. Investors - Lexicon Pharmaceuticals Investors Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions.